Rubraca is a PARP inhibitor which has currently been approved in the UK for ovarian cancer.
Rubraca was developed by the pharmaceutical company Clovis Oncology which specialises in cancer.
In the USA Clovis found that about half of prostate cancer patients on a Phase 2 trial who took Rubraca had their tumour shrink and/or their PSA levels decline. Based on this, the USA granted ‘accelerated approval’. This means that patients in the USA can take Rubraca if they have advanced prostate cancer which has spread outside the prostate, have genetic variants of BRCA genes and have already received both chemotherapy and at least one hormone therapy, such as abiraterone (Zytiga) or enzalutamide (Xtandi)
Rubraca is currently being studied in a phase 3 clinical trial. Despite the accelerated approval in the USA, it is likely that this phase 3 clinical trial will need to be completed (due to end in mid 2022) and a positive outcome confirmed in the trial before Rubraca can be considered for approval in prostate cancer in the UK.
To find out more about the typical timescales involved in developing new drugs and more information about clinical trials please click here.
You can find out more on the Clovis Oncology website here.
If you are interested in hearing updates about Rubraca’s development journey please fill out your details below and we will be sure to update you when we have news. This information will not be used for any purpose other than providing you updates on Rubraca and will not be shared outside our organisation.